Digital health technology for the end TB strategy: Developing priority products and making them work Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Enhanced diagnosis of tuberculosis using a dual gene target detection approach Source: International Congress 2016 – Microbiology: bronchoalveolar lavage (BAL) and PCR Year: 2016
TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Reading list PG10 Tuberculosis management: a personalised clinical approach Source: International Congress 2016 – PG10 Tuberculosis management: a personalised clinical approach Year: 2016
The European union standards for tuberculosis care: Do they need an update? Source: International Congress 2014 – Tuberculosis: public health and primary prevention Year: 2014
Evaluation of pulmonary TB treatment efficiency depending on polymorphism of glutathione-S-transferasexenobiotic biotransformation enzyme and on sensitivity profile Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Tuberculosis elimination: where are we now? Source: Eur Respir Rev, 27 (148) 180035; 10.1183/16000617.0035-2018 Year: 2018
Rapid monitoring of tuberculosis treatment response: A multi-centre study Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016
Global tuberculosis prevention: should we start from the beginning? Source: Eur Respir J, 54 (3) 1901394; 10.1183/13993003.01394-2019 Year: 2019
Tuberculosis: update on new diagnostic methods and treatment approach Source: Annual Congress 2007 - Infections year in review Year: 2007
Digital health for the End TB Strategy: developing priority products and making them work Source: Eur Respir J 2016; 48: 29-45 Year: 2016
Lymphocytopenia in pulmonary tuberculosis: Does it have a clinical value? Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016
Interpretation of indeterminate RIF-susceptibility results obtained by rapid molecular diagnostics test Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Multiplexed cytokine and chemokine profiling in patients with latent tuberculosis infection: Treatment effect Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention Year: 2014
Statin use and the risk of tuberculosis: Data from 305,142 patients Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
Cartridge based nucleic acid amplification technique (CBNATT) for diagnosis of rifampicin resistance from sputum smear in revised national tuberculosis control of India (RNTCP) – Implications of preliminary data Source: Annual Congress 2013 –Tuberculosis: clinical aspects Year: 2013
MDR-TB management: what is new? Source: School Course 2012 - TB and M/XDR-TB: from clinical management to control and elimination Year: 2012
Screening new entrants for tuberculosis in Liverpool; how practicable are current guidelines? Source: Eur Respir J 2002; 20: Suppl. 38, 23s Year: 2002
Is it necessary to give tuberculosis treatment daily throughout? Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014